Cell therapy

CHOP Researchers Develop Tool that Reduces Errors in Stem Cell Transplant Reporting

Retrieved on: 
Monday, January 23, 2023

PHILADELPHIA, Jan. 23, 2023 /PRNewswire/ -- Researchers at Children's Hospital of Philadelphia (CHOP) have developed a custom-built application to automate determination of engraftment, a key outcome after hematopoietic stem cell transplant (HSCT). The application supersedes a tedious manual process and at the same time substantially improves accuracy of reported hematopoietic cell transplant engraftments. The success of the tool, described recently in the journal Transplantation and Cellular Therapy, demonstrates how a unique embedded informatics team can rapidly build and implement applications that are useful in a clinical setting.

Key Points: 
  • --The tool, developed by hematopoietic cell transplant and informatics collaborators, improved transplant outcomes reporting required by regulators—
    PHILADELPHIA, Jan. 23, 2023 /PRNewswire/ -- Researchers at Children's Hospital of Philadelphia (CHOP) have developed a custom-built application to automate determination of engraftment, a key outcome after hematopoietic stem cell transplant (HSCT).
  • "Our experience building this application could serve as a blueprint for broad implementation of a similar tool, which would improve not only transplant reporting but also transplant research and practice."
  • Hematopoietic stem cell (HSC) transplant, also referred to as bone marrow or stem cell transplant, is a complex process used for the treatment of multiple types of malignant and non-malignant diseases in adults and children.
  • "Automation of Hematopoietic Cell Transplant Outcomes Reporting Leads to Dramatic Reduction of Errors Reported to Real-World Data Registry," Transplantation and Cellular Therapy, online January 5, 2023, DOI: 10.1016/j.jtct.2022.12.026

eGenesis Announces Knut Niss as Chief Technology Officer

Retrieved on: 
Tuesday, January 24, 2023

CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, today announced that Knut Niss, Ph.D., has joined the company as Chief Technology Officer.

Key Points: 
  • CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- eGenesis, a biotechnology company developing human-compatible organs and cells for the treatment of organ failure, today announced that Knut Niss, Ph.D., has joined the company as Chief Technology Officer.
  • “We are pleased to welcome Knut to the team and are confident he will help us advance our goal of transforming the treatment paradigm for organ failure,” said Michael Curtis, Ph.D., Chief Executive Officer of eGenesis.
  • “Synthetic biology and gene engineering are core components of our approach to developing high-quality, transplantable organs that ultimately save lives.
  • “Powered by a strong technological platform, eGenesis is well-positioned to address the hurdles that have hindered the field of xenotransplantation to date,” Dr. Niss said.

Global CAR T Cell Therapy Competitive Landscape 2022: Featuring Innovent Biologics, Sorrento Therapeutics, Cartesian Therapeutics and Novartis Among Others - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 11, 2023

This report provides comprehensive insights about 193+ companies and 450+ drugs in CAR T - Cell Therapy Competitive landscape.

Key Points: 
  • This report provides comprehensive insights about 193+ companies and 450+ drugs in CAR T - Cell Therapy Competitive landscape.
  • Abecma is the first cell-based CAR T - Cell Therapy approved by the FDA for the treatment of multiple myeloma.
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of CAR T - Cell Therapy?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the CAR T - Cell Therapy therapeutics?

The Alliance for Regenerative Medicine Appoints Mark Battaglini as Chief Strategy Officer

Retrieved on: 
Tuesday, January 3, 2023

Washington, D.C., Jan. 03, 2023 (GLOBE NEWSWIRE) -- The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization representing the cell and gene therapy sector, announced the appointment of Mark Battaglini to the newly created position of Chief Strategy Officer, effective today.

Key Points: 
  • Washington, D.C., Jan. 03, 2023 (GLOBE NEWSWIRE) -- The Alliance for Regenerative Medicine (ARM), the leading international advocacy organization representing the cell and gene therapy sector, announced the appointment of Mark Battaglini to the newly created position of Chief Strategy Officer, effective today.
  • Mr. Battaglini will be responsible for ARM’s global policy, government affairs, communications, and alliance development activities.
  • He will also lead the development of ARM’s strategy, mission, and vision, and guide the execution of the organization’s major priorities.
  • “I am honored for the opportunity to serve as ARM’s Chief Strategy Officer,” said Mr. Battaglini.

GT Biopharma Names Dr. Jeff Miller as Consulting Chief Medical Officer

Retrieved on: 
Wednesday, December 14, 2022

Dr. Miller’s current discovery and research themes in the Miller Laboratory include:

Key Points: 
  • Dr. Miller’s current discovery and research themes in the Miller Laboratory include:
    Simultaneous to Dr. Miller’s appointment GT Biopharma announces the departure of Dr. Greg Berk as President of Research & Development and Chief Medical Officer.
  • Michael Breen, Executive Chairman and Interim CEO of GT Biopharma commented on the occasion, “On behalf of the Company and the Board of Directors, we would like to welcome Dr. Jeff Miller once again to the role of consulting Chief Medical Officer.
  • TriKE® is a registered trademark owned by GT Biopharma, Inc.
    * Dr. Miller consults for and hold equity in GT Biopharma.
  • ** The University of Minnesota has a financial interest in GTB TriKE products including the GTB 3650 product under its license agreements with GT Biopharma.

UM171 cell therapy demonstrates improved outcomes compared to cord and matched unrelated donor peripheral blood transplants in real-world setting

Retrieved on: 
Monday, December 12, 2022

MONTRÉAL, Dec. 12, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today findings from a safety and efficacy retrospective analysis comparing outcomes of patients treated with ECT-001 (UM171-expanded) Cell Therapy in a Phase 1/2 trial to those treated with cord blood and matched unrelated donor peripheral blood stem cell transplants.

Key Points: 
  • MONTRÉAL, Dec. 12, 2022 (GLOBE NEWSWIRE) -- ExCellThera Inc. (ExCellThera), a world leader in blood stem cell expansion and rejuvenation, announced today findings from a safety and efficacy retrospective analysis comparing outcomes of patients treated with ECT-001 (UM171-expanded) Cell Therapy in a Phase 1/2 trial to those treated with cord blood and matched unrelated donor peripheral blood stem cell transplants.
  • In this real-world analysis using matched-controlled data from the CIBMTR® (Center for International Blood and Marrow Transplant Research®), ECT-001 Cell Therapy demonstrated improved outcomes compared to cord blood (CB) and matched unrelated donor (MUD) peripheral blood stem cell (PBSC) transplants, including overall survival (OS), progression-free survival (PFS), and graft-versus-host disease (GVHD) and relapse-free survival (GRFS).
  • “This matched-controlled real-world analysis strongly suggests that UM171-expanded Cell Therapy improves key long-term clinical outcomes for patients suffering from blood cancers who need a matched unrelated donor or a cord blood transplant.
  • “With a GRFS hazard ratio (HR) below 0.3 and 0.4 in favour of ECT-001 Cell Therapy versus standard of care matched unrelated donor or cord blood transplants, respectively (p

Astellas and MBC BioLabs Announce 2022 Future Innovator Prize Awarded to Bespoke Biotherapeutics and Cellinfinity Bio

Retrieved on: 
Tuesday, December 13, 2022

"We applaud the efforts of Bespoke Biotherapeuticsand Cellinfinity Bio for their advancements in immuno-oncology research and congratulate them for their achievement in winning this Future Innovator Prize.

Key Points: 
  • "We applaud the efforts of Bespoke Biotherapeuticsand Cellinfinity Bio for their advancements in immuno-oncology research and congratulate them for their achievement in winning this Future Innovator Prize.
  • It is our hope that this prize, in partnership with MBC BioLabs, will enable them to advance their science and turn their innovations into transformative treatments for patients around the world."
  • "We are very pleased to be awarded an Astellas Future Innovation Prize," said Steven R. Deitcher, M.D., CEO, Bespoke Biotherapeutics.
  • Both Bespoke Biotherapeutics and Cellinfinity Bio will reside at MBC BioLabs with the next year sponsored by Astellas.

ExCellThera announces completion of Phase 2 clinical trials for UM171-expanded cell therapy in high-risk blood cancers

Retrieved on: 
Tuesday, November 15, 2022

The data ExCellThera is collecting from clinical trials to date demonstrate that ECT-001 Cell Therapy is safe, reduces the incidence of severe complications and improves outcomes for patients who require blood stem cell transplants, said Pierre Caudrelier, MD, Chief Medical Officer of ExCellThera.

Key Points: 
  • The data ExCellThera is collecting from clinical trials to date demonstrate that ECT-001 Cell Therapy is safe, reduces the incidence of severe complications and improves outcomes for patients who require blood stem cell transplants, said Pierre Caudrelier, MD, Chief Medical Officer of ExCellThera.
  • ECT001 Cell Therapy has been evaluated in over 100 adult and pediatric patients with severe blood disorders in several clinical trials in the United States and Canada (with additional clinical trials in Europe expected soon).
  • ExCellTheras lead proprietary molecule, UM171, has become the standard for hematopoietic stem cell (HSC) expansion in cell and gene therapy.
  • In addition to ECT-001 Cell Therapy, ExCellThera also has a pre-clinical pipeline of next generation cell & gene therapies in adjacent fields of use.

Rutgers Cancer Institute of New Jersey and RWJBarnabas Health to Showcase Novel and Expansive Hematology/Oncology Data at the 64th American Society of Hematology Annual Meeting and Exposition

Retrieved on: 
Tuesday, November 15, 2022

NEW BRUNSWICK, N.J., Nov. 15, 2022 /PRNewswire/ -- Physician-scientists from Rutgers Cancer Institute of New Jersey and RWJBarnabas Health will present a wide-ranging scope of new hematology/oncology data from their clinical research program at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, being held in New Orleans, Louisiana (and virtually) from December 10-13, 2022. A total of 24 abstracts have been accepted, comprising clinical data and analyses that advance the understanding and treatment of such blood cancers as lymphoma, leukemia and myeloma. Rutgers Cancer Institute, together with RWJBarnabas Health, is New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state.

Key Points: 
  • A total of 24 abstracts have been accepted, comprising clinical data and analyses that advance the understanding and treatment of such blood cancers as lymphoma, leukemia and myeloma.
  • Rutgers Cancer Institute, together with RWJBarnabas Health, is New Jersey's only National Cancer Institute-designated Comprehensive Cancer Center and the leading cancer program in the state.
  • Pola is an antibody-drug conjugate that is safe and effective when combined with chemotherapy in frontline and relapsed, transplant-ineligible DLBCL patients.
  • The full list of presentations at this year's ASH Annual Meeting and Exposition follows:

Artiva Biotherapeutics Presents Preclinical Data for AB-101, an Optimized Allogeneic NK Cell Therapy Candidate, at SITC 2022 Annual Meeting

Retrieved on: 
Thursday, November 10, 2022

The data were presented at the Society for Immunotherapy of Cancer (SITC) 37TH Annual Meeting in Boston.

Key Points: 
  • The data were presented at the Society for Immunotherapy of Cancer (SITC) 37TH Annual Meeting in Boston.
  • Artiva is also developing a combination therapy comprised of AB-101 and Affimed N.V.s Innate Cell Engager AFM13 for treatment of patients with relapsed/refractory CD30-positive lymphomas.
  • AB-101 is a cord blood-derived, allogeneic, cryopreserved, ADCC-enhancing NK cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers.
  • Artiva has entered into therapeutic NK cell collaborations with Merck Sharp & Dohme Corp. and with Affimed GmbH.